Sensible Biotechnologies
Novel mRNA manufacturing paradigm to establish critical biomanufacturing infrastructure for global biosecurity.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | $4.2m | Seed | |
| Total Funding | 000k | ||
Related Content
A biotechnology company developing a cell-based platform for designing and manufacturing mRNA therapeutics. The company aims to overcome the limitations of synthetic mRNA by using a proprietary, AI-powered design and optimization platform to produce pure, low-cost, and effective mRNA medicines.
Sensible Biotechnologies' platform models RNA folding from raw sequence data to predict and design precise mRNA sequences. This approach has been shown to reduce the time required to optimize novel cell-based mRNA therapeutics by over 90%. The company's mission is to unlock the next generation of mRNA medicines by providing a cost-efficient and scalable manufacturing process. The company has secured $4.2 million in a pre-seed funding round to advance the development of its platform.
Keywords: mRNA, cell-based platform, therapeutics, biotechnology, AI-powered design, drug discovery, genetic medicine, RNA folding, biomanufacturing, oncology